141 related articles for article (PubMed ID: 28425810)
1. Candesartan, an Insurmountable Antagonist of Angiotensin II-mediated Contractile Effects in Isolated Vascular Preparations: Comparison with Irbesartan, Losartan and its Active Metabolite (EXP-3174).
Morsing U Brandt-Eliasson L Renberg T Abrahamsson P
Blood Press; 2000; 9(sup1):50-51. PubMed ID: 28425810
[TBL] [Abstract][Full Text] [Related]
2. Candesartan Causes Long-lasting Antagonism of the Angiotensin II Receptor-mediated Contractile Effects in Isolated Vascular Preparations: a Comparison with Irbesartan, Losartan and its Active Metabolite (EXP-3174).
Abrahamsson T; Karp L; Brandt-Eliasson U; Morsing P; Renberg L; Sjöquist PO
Blood Press; 2000; 9(sup1):52. PubMed ID: 28425811
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
Morsing P; Adler G; Brandt-Eliasson U; Karp L; Ohlson K; Renberg L; Sjöquist PO; Abrahamsson T
Hypertension; 1999 Jun; 33(6):1406-13. PubMed ID: 10373224
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
Israili ZH
J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
[TBL] [Abstract][Full Text] [Related]
5. Sympatho-inhibitory properties of various AT1 receptor antagonists.
Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
J Hypertens Suppl; 2002 Jun; 20(5):S3-11. PubMed ID: 12184061
[TBL] [Abstract][Full Text] [Related]
6. Functional antagonism of different angiotensin II type I receptor blockers in human arteries.
Wagenaar LJ; Voors AA; Buikema H; van Buiten A; Lübeck RH; Boonstra PW; van Veldhuisen DJ; van Gilst WH
Cardiovasc Drugs Ther; 2002 Jul; 16(4):311-6. PubMed ID: 12652100
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the AT1-receptor blockers candesartan, irbesartan and losartan for inhibiting renal microvascular constriction.
van Rodijnen WF; van Lambalgen TA; van Teijlingen ME; Tangelder GJ; Ter Wee PM
J Renin Angiotensin Aldosterone Syst; 2001 Mar; 2(1_suppl):S204-S210. PubMed ID: 28095224
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man.
Fuchs B; Breithaupt-Grögler K; Belz GG; Roll S; Malerczyk C; Herrmann V; Spahn-Langguth H; Mutschler E
J Pharm Pharmacol; 2000 Sep; 52(9):1075-83. PubMed ID: 11045887
[TBL] [Abstract][Full Text] [Related]
9. Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors.
Vanderheyden PM; Fierens FL; De Backer JP; Fraeyman N; Vauquelin G
Br J Pharmacol; 1999 Feb; 126(4):1057-65. PubMed ID: 10193788
[TBL] [Abstract][Full Text] [Related]
10. Sympatholytic properties of several AT1-receptor antagonists in the isolated rabbit thoracic aorta.
Nap A; Balt JC; Pfaffendorf M; Van Zwieten PA
J Hypertens; 2002 Sep; 20(9):1821-8. PubMed ID: 12195125
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of angiotensin II receptors in isolated human subcutaneous resistance arteries.
Ytterberg H; Edvinsson L
J Renin Angiotensin Aldosterone Syst; 2001 Mar; 2(1_suppl):S37-S41. PubMed ID: 28095233
[TBL] [Abstract][Full Text] [Related]
12. Is it Possible to Differentiate between Angiotensin II Type 1 (AT1) Receptor Blockers in Normotensive Volunteers?
Azizi M; Chatellier G; Nicolet L; Guyene T; Hempenius J; Ménard J
Blood Press; 2000; 9(sup1):53. PubMed ID: 28425793
[TBL] [Abstract][Full Text] [Related]
13. Effects of the insurmountable angiotensin AT1 receptor antagonist candesartan and the surmountable antagonist losartan on ischemia/reperfusion injury in rat hearts.
Wang QD; Sjöquist PO
Eur J Pharmacol; 1999 Sep; 380(1):13-21. PubMed ID: 10513555
[TBL] [Abstract][Full Text] [Related]
14. Functional comparison of the antagonistic properties of some Angiotensin II type 1 receptor blockers on the contraction elicited by Angiotensin II and thromboxane A2 on human saphenous veins.
Hakim A; Stanke-Labesque F; Hoffmann P; Sessa C; Caron F; Cracowski JL; Bessard G
J Cardiovasc Pharmacol; 2003 Jul; 42(1):42-7. PubMed ID: 12827025
[TBL] [Abstract][Full Text] [Related]
15. Effects of irbesartan (SR47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: potential mechanisms of action.
Christophe B; Libon R; Cazaubon C; Nisato D; Manning A; Chatelain P
Eur J Pharmacol; 1995 Aug; 281(2):161-71. PubMed ID: 7589203
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vivo effects of irbesartan and losartan on angiotensin II receptor binding in the rat kidney following oral administration.
Fabiani ME; Dinh DT; Nassis L; Casley DJ; Johnston CI
Clin Sci (Lond); 2000 Oct; 99(4):331-41. PubMed ID: 10995600
[TBL] [Abstract][Full Text] [Related]
17. Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different?
Unger T
Am J Cardiol; 1999 Nov; 84(10A):9S-15S. PubMed ID: 10588089
[TBL] [Abstract][Full Text] [Related]
18. AT(1)-receptor blockers: differences that matter.
Gradman AH
J Hum Hypertens; 2002 Aug; 16 Suppl 3():S9-S16. PubMed ID: 12140723
[TBL] [Abstract][Full Text] [Related]
19. Distinctions between non-peptide angiotensin II AT1-receptor antagonists.
Vauquelin G; Fierens FL; Verheijen I; Vanderheyden PM
J Renin Angiotensin Aldosterone Syst; 2001 Mar; 2(1_suppl):S24-S31. PubMed ID: 28095245
[TBL] [Abstract][Full Text] [Related]
20. Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type 1 receptors.
Vanderheyden PM; Fierens FL; De Backer J; Vauquelin G
Biochem Pharmacol; 2000 Apr; 59(8):927-35. PubMed ID: 10692557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
